Various prostatic disorders are described in older intact dogs. Progression of disease commences quite often in dogs aged 5.5 years or older. Clinical symptoms are transient in the beginning, and are difficult to recognize. In fact, patient feels very little, if any, discomfort as troubles develop subsequently. As an exception to the rule there is acute inflammation, symptoms of which are severe, sometimes even life threatening. Diagnosis not meticulously established, when procedure is not met properly, (e.g. recognition of prostatitis without identification of infectious agent) this may result in development of chronic disease, which is often hard to manage. Rectal palpation should be part of routine examination in all older dogs, while correct diagnostic protocol should follow. By means of precise diagnostic protocol, we are able to identify the problem early, often in the curable stage of disease; therefore we are able to maintain fertility of the patient, as well. So far, described prostatic disorders are benign hyperplasia (BPH), squamous metaplasia, prostatic inflammation, both acute and chronic, prostatic cysts and abscesses and neoplasia.
It was concluded that, in the authors' facility, treatment of prostatic cancer by subtotal intracapsular prostatectomy was superior to that by total prostatectomy, with respect to both postoperative survival and serious complications.
Summary. Although hirudin is better than heparin at preventing recurrent ischemia in patients with unstable angina, hirudin produces more bleeding. The purpose of this study was to use a rabbit arterial thrombosis prevention and ear bleeding model to determine whether for equivalent efficacy, melagatran, a synthetic direct thrombin inhibitor, is safer than hirudin. A combination of balloon injury and stasis was used to induce thrombosis in the distal aorta, and patency and blood flow were continuously monitored with ultrasonic flow probes. Rabbits were randomized to melagatran (in total doses of 78-313 nmol kg À1 ), hirudin (in total doses of 18-107 nmol kg À1 ), or saline over 90 min. To assess safety, blood loss from standardized ear incisions was measured. Both melagatran and hirudin produced dose-dependent increases in patency and blood flow. At doses that maintained the highest levels of patency, however, melagatran produced 2-3-fold less bleeding than hirudin. Thus, at maximally effective doses, melagatran causes less bleeding than hirudin in this model. These findings raise the possibility that some direct thrombin inhibitors are safer than others.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.